Gene Therapy Not Cost-Effective for Sickle Cell by Conventional Measures
The inequality aversion parameter would need to be 0.90 for gene therapy to be preferred per distributional cost-effectiveness analysis standards
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.